Representative trials: (i) CD1d-restricted CAR19-NKT eradicate brain lymphomas & elevated cytotoxicity against CD19+ CLL cells (106); (ii) CSPG4-specific CAR-NKT kill melanoma in vitro with improved cytotoxicity (107); (iii) CD62L-CD19 CAR-NKT complete B-cell lymphoma regression in mice (108). This evidence concerns the gene SELL and B-cell chronic lymphocytic leukemia.